Abstract：Objective To study the characteristics of blood coagulation index concentration change in tumor patients. Methods 115 cancer pationts were divided into groups of stomach cancer, colon cance and lung cancer. For the patients, the levels of blood clotting index before and after chemotherapy coagulation index changes over time were detected and blood coagulation indexes were detected in 50 cases of control group. Results In patients with cancer, plasma prothrombin time (PT) (12.39±1.23)s, activated partial thromboplastin time (APTT) (30.58±7.43)s, fibrinogen (FIB) (4.71±1.72)g/L, D- dimer (D-Dimer) (1.32±0.16 )μg/ml levels were significantly higher than in the control group (P<0.05). In patients with different types of tumor plasma PT, APTT, FIB, D-Dimer levels were significantly higher than in the control group (P<0.05). In lung cancer group, plasma FIB level was significantly higher than in colorectal cancer group and gastric cancer group (P<0.05). The plasma FIB level in gastric cancer group and colorectal cancer group was not significantly different. In gastric cancer group, lung cancer group and colorectal cancer group, plasma FIB levels did not obviously change in different periods of chemotherapy. Conclusions Coagulation indices for tumor diagnosis and curative effect monitoring have some help and are good indicators to excluded tumor, and preven venous thrombosis.
王会芳，于彩霞，王家坡，王国增，张硕，王丽丽，李立霞，朱丽莉，匡铁吉. 恶性肿瘤患者凝血指标浓度变化特点分析[J]. 武警医学, 2016, 27(1): 26-28.
WANG Huifang, YU Caixia, WANG Jiapo, WANG Guozeng, ZHANG Shuo, WANG Lili, LI Lixia, ZhuLili,and KUANG Tieji. Clinical analysis of routine blood coagulation index concentration change in 115 cancer patients. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(1): 26-28.
Ahlbrecht J, Dickmann B, et al. Tumer grade is associated with venous thrombeoembolism in patients with cancer:result from the Vienna cancerand Thrombosis study[J] .J Clin Oncol,2012,30(31):3870-3875.
[2]
Tormoen G M, Haley K M, Levine R L, et al. Do circulating tumor cells play a role in coagulation and thrombosis[J]. Front Oncol, 2012, 10 (2):115.
[3]
Demer M,Krause D S,schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis[J].Proc Natl Acad Sci USA,2012,109(32):13076-13081.
[4]
Khorana A A, Francis C W, Culakova E, et al. Frequency, risk factor, and trends for venous thromboembolism among hospitalized cancer patients[J].Cancer,2007,110(10):2339-2346.
[5]
Menapace L A,Khorana A A. The role of thromboprophylaxis in cancer patients:emerging data[J]. Curr Opin Hematol, 2010,17(5):450-456.
[6]
Donati M B, Falanga A. Pathogenetic mechanisms of thrombosis in malignancy[J].Acta Haematol, 2001,106(1-2):18-24.
[7]
Haddad T C,Greeno E W. Chemotheraapy-induced thrombosis[J].Thromb Res,2006,118(5):555-568.
[8]
Khorana A A. Venous thromboembolism and prognosis in cancer[J].Thromb Res,2010,125(6):490-493.
Kono T, Ohtsuki N, et al.Clinical characteristics of ischemic stroke in eldely patient with cancer[J].Nihon Ronen Igakkai Zasshi,2011,48(1):57-62.
[12]
Mochizuki S, Yoshino T, Kojima T, et al.Therapeutic significance of a D-dimer cut-off level of>3цg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab[J]. Jpn J Clin Oncol,2010,40(10):933-937.
2016, Vol. 27 
